Instruction 1(b).

FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

wasiiiigtoii,	D.C. 20049

wasiiiigtori, D.C. 20045	OMB APPROVAL			
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP	OMB Number:	3235-0287		

Check this box if no longer subject								
to Section 16. Form 4 or Form 5								
obligations may continue. See								

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OIVIB APPROVAL								
OMB Number: 3235-0287								
Estimated average burden								
hours per response:	0.5							

1. Name and Address of Reporting Person* <u>LILLY ENDOWMENT INC</u>					EL	2. Issuer Name and Ticker or Trading Symbol ELI LILLY & Co [ LLY ]									Relationship of Reporting Person(s) to Issu (Check all applicable)  Director X 10% Owner  The Company of t				vner	
(Last)	(Fir	st) (N	∕liddl	e)	3. Date of Earliest Transaction (Month/Day/Year) 03/24/2023									Office	er (give title /)		Other (sbelow)	specify		
2801 NORTH MERIDIAN STREET				4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)									Individual or Joint/Group Filing (Check Applicable Line)						
(Street)														X Form filed by One Reporting Person						
INDIANAPOLIS IN 46208-0068				8-0068		Form filed by More than One Reporting Person										orting				
(City) (State) (Zip)					Rı	Rule 10b5-1(c) Transaction Indication														
						Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.														
		Table	I - I	Non-Deriva	tive	Secui	rities	Acc	quir	ed, C	Dis	posed o	f, or	Benefici	ially	Own	ed			
1. Title of Security (Instr. 3)				2. Transaction Date (Month/Day/Ye	ear) Execution		on Date,		3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 an				nd 5) Secur Benef Owne		ities Ficially (I d Following Ir		n: Direct r ect (I)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
							C		ode	v	Amount (/		(A) or (D)	Price		Reported Transaction(s) (Instr. 3 and 4)		(iiist	1. 4)	(111511. 4)
Common Stock				03/24/2022	3				S			81,976	D	D \$335.745 <sup>(1)</sup>		5(1) 102,766,834		D		
Common	Stock			03/24/202	3						18,024		D	\$336.60	8(2)	102,748,810		D		
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	Exe if ar	Deemed cution Date, ny nth/Day/Year)	4. Transaction Code (Instr. 8) 5. Num of Derivat Securit Acquir (A) or Dispos of (D) (Instr. 1 and 5)			vative (Month/Durities aired or osed )) r. 3, 4			n Date Asay/Year) S U D S		Amo Secu Unde Deriv Secu	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		rice of ivative curity tr. 5)	9. Number derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	Ownershi Form: Direct (D) or Indirec (I) (Instr. 4		11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code	Code V (A) (D)				Date Exercisable		Expiration Date	Title	Amount or Number of Shares						

## **Explanation of Responses:**

1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$335.50 to \$336.495, inclusive. The reporting person undertakes to provide to Eli Lilly & Company, any security holder of Eli Lilly & Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) and (2) to this Form 4.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$336.50 to \$336.79, inclusive.

## Remarks:

/s/Peter A. Buck, Vice President for Investments & Grants Administration, on behalf of Lilly Endowment

03/27/2023

Inc.

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.